非典型ALK/ROS1/RET基因组断点预测NSCLC靶向疗效不可靠
研究分析3787例NSCLC样本,评估ALK、ROS1、RET基因组断点位置能否预测匹配靶向治疗疗效。发现非典型融合中12.8%为非生产性重排,且85.4%的非典型融合实际产生典型转录本;非典型ALK融合一线克唑替尼PFS短于典型融合,但仅分析RNA或蛋白阳性病例时无差异。
要点
- 非典型ALK/ROS1/RET基因组断点不能可靠预测靶向治疗疗效
- 非典型融合中部分为非生产性重排,需RNA或蛋白功能验证
- 仅RNA或蛋白阳性病例中,非典型与典型ALK融合PFS无差异
核心结论
- 非典型ALK、ROS1、RET基因组断点是不匹配靶向治疗疗效的不可靠预测因子。
研究设计与样本
- 回顾性分析3787例NSCLC样本,采用DNA NGS、靶向RNA NGS、全转录组测序和免疫组化检测。
主要发现
- DNA NGS检出ALK融合241例、ROS1融合59例、RET融合76例。
- 47例非典型融合中6例(12.8%)为非生产性重排,不产生异常转录本或蛋白。
- 典型ALK和RET融合的基因组断点均预测转录本断点,而ROS1融合未显示此关联。
- 85.4%(35/41)的非典型融合实际产生典型融合转录本。
- 非典型ALK融合(n=31)一线克唑替尼中位PFS短于典型融合(n=53)(8.4个月 vs 12.0个月,p=0.004);仅分析ALK RNA或蛋白阳性病例时PFS无差异(p=0.185)。
临床怎么用
- 对罕见ALK、ROS1、RET融合,建议通过RNA或蛋白 assay 进行功能验证以准确解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Variable genomic breakpoints have been identified through the application of target-capture DNA next-generation sequencing (NGS) for ALK, ROS1, and RET fusion detection in NSCLC. We investigated whether ALK, ROS1, and RET genomic breakpoint location can predict matched targeted therapy efficacy. METHODS: NSCLCs were analyzed by DNA NGS, target-specific RNA NGS, whole-transcriptome sequencing, and immunohistochemistry. RESULTS: In total, 3787 NSCLC samples were analyzed. DNA NGS detected ALK, ROS1, and RET fusions in 241, 59, and 76 cases, respectively. These fusions were divided into canonical (single EML4-ALK, CD74/EZR/TPM3/SDC4-ROS1, and KIF5B/CCDC6-RET fusions), noncanonical (single non-EML4-ALK, non-CD74/EZR/TPM3/SDC4-ROS1, and non-KIF5B/CCDC6-RET fusions), and primary/reciprocal (both primary and reciprocal rearrangements were detected) subtypes on the basis of genomic breakpoint position, and noncanonical and primary/reciprocal subtypes were defined as uncommon fusions. Further RNA sequencing and immunohistochemistry revealed that six of 47 (12.8%) uncommon fusions were actually nonproductive rearrangements that generated no aberrant transcripts or proteins. Moreover, genomic breakpoints of canonical ALK and RET, but not ROS1, fusions always predicted breakpoints at the transcript level, whereas 85.4% (35 of 41) of uncommon fusions actually produced canonical fusion transcripts. Patients with uncommon ALK fusion (n = 31) who received first-line crizotinib exhibited shorter median progression-free survival than those with canonical ALK fusion (n = 53, 8.4 mo versus 12.0 mo, p = 0.004). However, no difference in progression-free survival was observed when only ALK RNA or protein-positive cases were analyzed (p = 0.185). CONCLUSIONS: Uncommon ALK, ROS1, and RET genomic breakpoint is an unreliable predictor of matched targeted therapy efficacy. Functional validation by RNA or protein assay may add value for the accurate detection and interpretation of rare fusions.
引用
- Li W, Guo L, Liu Y, et al. Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC. J Thorac Oncol. 2020. PMID: 33248323. doi:10.1016/j.jtho.2020.10.156
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。